CD22 and non-Hodgkin lymphoma: We chose a ~ 3Kb CD19-CD22 dual CAR construct that has demonstrated anti-tumor function for potential treatment of patients with Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin’s lymphoma (NHL) (Fig. 6A and Fry et al., 2018).